Incretin medications, like semaglutide and tirzepatide, suppress appetite and delay gastric emptying, facilitating weight loss and begging the question of the need for concurrent behavior change therapy. These medications have been dubbed a game changer in obesity treatment and inflection point in the industry . They address the biological drivers of obesity – closing the gap in weight lost between lifestyle and surgical approaches. This session will explore the role of behavior change therapy during weight loss medication use. CME/CE Expiration Date: 4/26/27 *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
- Provider:Obesity Medicine Association
- Activity Link: https://academy.obesitymedicine.org/node/6205
- Start Date: 2024-04-29 05:00:00
- End Date: 2024-04-29 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest